Sun Pharma Introduces "Leave Acne Behind™" Patient Initiative in USA

PRINCETON, N.J., Jan. 23, 2017 /PRNewswire/ -- Sun Pharma has introduced "Leave Acne Behind™", an unique initiative dedicated to educate patients and create awareness of severe recalcitrant nodular acne (SRNA).

Approximately 50 million people in the US suffer from acne breakouts and flare-ups. Out of all of the prescription- treated acne cases today, 20 percent represent severe acne conditions. Those who face such conditions often suffer embarrassment, low self-esteem and other negative emotions that impact their quality of life. Approximately, 90% of these cases are often teenagers.

Leave Acne Behind initiative comprise a suite of educational resources including a website LeaveAcneBehind.com and resources at the dermatologist's office including a book (both in hard copy and iBook) and patient brochure to help patients and caregivers navigate through topics that are often not addressed regarding severe acne. All of the program's resources are meant to open the lines of communication between patients and dermatologists in hopes to reduce the long-term effects of acne.

The website and book addresses variety of topics such as:

• Who gets acne and why
• The different types of acne
• The physical and emotional damage severe acne can cause
• Treatments to help prevent acne from causing permanent skin damage, ex. scars
• Questions a patient or caregiver may want to ask during dermatology health care provider appointments

"For anyone looking to educate themselves on acne, including severe recalcitrant nodular acne and help them make informed treatment decisions, the "Leave Acne Behind" initiative is a great resource," said Dr. Jeremy Moss, M.D., Ph.D., a board certified dermatologist and an associate professor of dermatology at Yale University. "Patients and caregivers can use these education and awareness materials to speak to their dermatologist."

Please visit LeaveAcneBehind.com for more information. The Leave Acne Behind resource book and patient brochure can be found in most dermatologist offices nationwide.

About Sun Pharmaceutical Industries Ltd. (CIN – L24230GJ1993PLC019050)
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 47 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2016 are approximately US$ 4.3 billion, of which US contributes US$ 2.1 billion. In India, the Company enjoys leadership across 12 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 8% of annual revenues.

For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

SOURCE Sun Pharma

Related Links

http://www.sunpharma.com